Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018036243) TISSUE FACTOR-TARGETED ANTIBODY-DRUG CONJUGATE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/036243 International Application No.: PCT/CN2017/087779
Publication Date: 01.03.2018 International Filing Date: 09.06.2017
IPC:
A61K 47/68 (2017.01) ,A61K 31/537 (2006.01) ,A61P 35/00 (2006.01) ,C07K 16/36 (2006.01)
[IPC code unknown for A61K 47/68][IPC code unknown for A61K 31/537][IPC code unknown for A61P 35][IPC code unknown for C07K 16/36]
Applicants:
复旦大学 FUDAN UNIVERSITY [CN/CN]; 中国上海市 杨浦区邯郸路220号 No.220, Handan Road, Yangpu District Shanghai 200433, CN
中国科学院上海药物研究所 SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN/CN]; 中国上海市 浦东张江祖冲之路555号 No. 555 of Zuchongzhi Road, Zhangjiang, Pudong District Shanghai 201203, CN
上海美雅珂生物技术有限责任公司 SHANGHAI MIRACOGEN INC. [CN/CN]; 中国上海市 浦东新区中国(上海)自由贸易试验区张江路1238弄2号3层E、F、G、H座 Suite 3E, F, G, H, Building 2, No. 1238 Zhangjiang Rd., China (Shanghai) Pilot Free Trade Zone Pudong New Area, Shanghai 201203, CN
Inventors:
余科 YU, Ke; CN
沈竞康 SHEN, Jingkang; CN
孟韬 MENG, Tao; CN
马兰萍 MA, Lanping; CN
张学赛 ZHANG, Xuesai; CN
李晴柔 LI, Qingrou; CN
Agent:
上海一平知识产权代理有限公司 XU & PARTNERS, LLC.; 中国上海市 普陀区真北路958号天地科技广场1号楼106室 Room No.106, Building No.1, Universal High-Tech Plaza, 958 Zhen Bei Road, Putuo District Shanghai 200333, CN
Priority Data:
201610704559.122.08.2016CN
201710125244.603.03.2017CN
Title (EN) TISSUE FACTOR-TARGETED ANTIBODY-DRUG CONJUGATE
(FR) CONJUGUÉ ANTICORPS-MÉDICAMENT CIBLANT LE FACTEUR TISSULAIRE
(ZH) 靶向于组织因子的抗体-药物偶联物
Abstract:
(EN) A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to a TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and a significant anti-tumor effect.
(FR) L'invention porte sur un conjugué anticorps-médicament (ADC) ciblant le facteur tissulaire (TF) et sur un procédé de préparation de l'ADC. L'ADC est capable de se lier à un antigène du TF avec une haute spécificité, une haute affinité, une faible immunogénicité, une haute cytotoxicité, et un effet antitumoral significatif.
(ZH) 靶向于组织因子的抗体-药物偶联物以及制备该抗体-药物偶联物(ADC)的方法。该ADC能够高特异性地结合TF抗原,其具有很高的亲和力、很低的免疫原性,以及很高的细胞毒性,并且具有显著的抗肿瘤作用。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)